Meeting
2022 ASCO Genitourinary Cancers Symposium
Healthcare resource utilization (HRU) and costs among patients with Von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC): A retrospective administrative claims analysis.
Authors
Eric Jonasch
The University of Texas MD Anderson Cancer Center, Houston, TX
Eric Jonasch , Yan Song , Jonathan Freimark , Richard Berman , Ha Nguyen , James Signorovitch , Murali Sundaram
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 305)
DOI
10.1200/JCO.2022.40.6_suppl.305
Abstract #
305
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Burden of surgeries and surgical complications in patients with Von Hippel Lindau (VHL) disease before and after treatment with belzutifan.
First Author: Lin Wang
Poster
2023 ASCO Annual Meeting
The impact of surgery on patients with VHL-associated tumors: An international patient survey.
First Author: Murali Sundaram
Poster
2024 ASCO Genitourinary Cancers Symposium
Systemic and surgical treatment in renal cell carcinoma: Does timing matter?
First Author: Konstantin Egon Seitzer
Poster
2023 ASCO Annual Meeting
Belzutifan treatment of Von Hippel-Lindau (VHL) related central nervous system (CNS) hemangioblastomas (HBs): A single institution experience.
First Author: Othon Iliopoulos